In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster Session 2: Chronic Heart Failure – Pathophysiology and Mechanisms
Session

Event : Heart Failure 2018

Topic : Other

  • Session type : Poster Session
  • Date : 27 May 2018
  • Time : 08:30 - 18:00

47 presentations in this session

The occurence of Heart failure result in low weight at birth in woman with congenital heart disease

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : S Bele (Tirana,AL)

Relationship between serotonergic-modulating psycoactive treatments and 24-hour Cheyne-Stokes respiration occurrence in systolic heart failure.

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : G Mirizzi (Pisa,IT)

The association between markers of fibrosis and myocardial dyssynchrony in patients with CHF

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Bilchenko (Kharkov,UA)

Circulating biomarkers of inflammation and left ventricular hypertrophy in patients with heart failure with preserved ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Bilchenko (Kharkov,UA)

Radiation induced valve disease and cardiotoxicity induced heart failure is frequent

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Bergler-Klein (Vienna,AT)

Dual cardioprotection improves right and left ventricular systolic function in patients receiving cardiotoxic chemotherapy

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Ferreira (London,GB)

Cancer therapeutic related cardiac dysfunction among active breast cancer patients: A Cardio-Oncology registry

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Laufer-Perl (Tel Aviv,IL)

Mesalazine-induced cardiotoxicity: a retrospective study initial results

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : C Goena Vives (San Sebastian,ES)

Haemodynamic changes associated with Cheyne-Stokes respiration in patients with heart failure: an echocardiographic study

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Giannoni (S. Croce S/Arno,IT)

Combined post- and pre-capillary pulmonary hypertension in heart transplant candidates with ischemic versus nonischemic etiology

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : Z Bayram (Istanbul,TR)

Effect of ischemic versus nonischemic cardiomyopathy on invasive hemodynamic findings in heart transplant candidates

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : Z Bayram (Istanbul,TR)

Experience using sacubitril/valsartan in real life: tolerability and clinical evolution in a long term

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : R Bravo Marques (Marbella,ES)

What is the significance of right ventricular dysfunction in patients with preserve, mid-range and depressed LVEF?

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : S Del Prado Diaz (Madrid,ES)

Echocardiographic evaluation of left ventricular filling pressures in patients with pulmonary hypertension

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Schneider (Vienna,AT)

Metabolic syndrome phenotypes have different effects on the diastolic function of the left ventricle and arterial ageing

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Jakstaite (Duesseldorf,DE)

Diastolic dysfunction of the right ventricle as an early diagnostic marker of heart failure

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : V Kirillova (Ekaterinburg,RU)

Early circulating predictors of post-infarction myocardial remodeling pattern

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Ivanov (Chisinau,MD)

Early left ventricular reverse remodelling after sacubitril/valsartan treatment in clinical practice

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Galvan Ruiz (Las Palmas De G. C.,ES)

Dynamical 3D modeling possibilities in the left ventricle reconstructions Personalized surgical approach in cardiac surgery

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : I Barabas (Erd,HU)

Corrected QT interval and right shifted association with mortality in acute heart failure patients

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : HY Lee (Seoul,KR)

Long term outcome and factors associated with reduced systolic ventricular function in survivors of sudden cardiac arrest

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : H Soeholm (Copenhagen Nv,DK)

Ivabradine in the treatment of heart failure with reduced ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : G Dadashova (Baku,AZ)

Endocrine hormonal imbalance in heart failure with reduced ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Naegele (Zurich,CH)

Reduction in the number of heart failure hospitalizations in patients included in a heart failure unit.

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : V Martinez Dosantos (Madrid,ES)

Predictors of recovery of left ventricular ejection fraction in patients included in a heart failure unit

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : D Iglesias del Valle (Madrid,ES)

Reduction of the need for diuretic treatment in patients included in a heart failure unit

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : V Martinez Dosantos (Madrid,ES)

Ejection fraction monitoring in patients with heart failure: the improved ejection fraction as a prognostic marker

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : ML Coronel (Corrientes,AR)

Efficacy of heart failure reversal treatment followed by 90 days follow up in chronic heart failure patients with low ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : R Sane (Thane,IN)

The impact of coronary artery disease on clinical outcomes in heart failure with mid-range ejection fraction patients

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : JC Choe (Busan,KR)

The value of bioimpedance vector analysis in decompensated heart failure patients with mid-range ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Klimenko (Moscow,RU)

Left ventricular systolic dysfunction before planned surgical revascularization: "grey area" features

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : O Yepanchintseva (Kyiv,UA)

Heart failure with mid-range ejection fraction: characteristics and outcome in patients with and without acute kidney injury

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : IR Lala (Arad,RO)

Mortality in patients with heart failure and midrange ejection fraction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Xavier Fontes (Vila Franca Do Campo,PT)

Impact of hypoalbuminemia in heart failure with preserved ejection fraction: a future therapeutic target?

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : M Pires (Viseu,PT)

Design and rationale of the EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure (EMPEROR-Preserved)

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : J Butler (Atlanta,US)

Independent predictors of sudden cardiac death in patients with ischemic chronic heart failure with preserved ejection fraction and renal dysfunction

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : D Lashkul (Zaporizhzhia,UA)

What influences exercise capacity in male and female with heart failure and preserved ejection fraction of left ventricle?

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : E Chernyaeva (Kiev,UA)

Norepinephrine, plasma renin activity and prognosis in chronic systolic heart failure

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Aimo (Pisa,IT)

Clinical outcome and prognosis in patient with acute heart failure

Event : Heart Failure 2018

  • Session : Chronic Heart Failure – Pathophysiology and Mechanisms
  • Speaker : A Tahilyani (United Kingdom,GB)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are